Apr. 9 at 12:52 PM
Heads Up Traders
👉Click to view @NasdaqPulse for timely updates amid the volatility.
$ORKA &
$SYRE are coming for
$ABBV’s Skyrizi in Psoriasis & IBD respectively. Crazy market shifts as bio funds reallocate—up BIG last year, but both still YEARS away from phase 3.
On the flip side,
$VKTX is going head-to-head with
$LLY’s Tirzepatide in obesity, already deep into phase 3. But here's the kicker: Most competing obesity drugs are falling short, and there’s a massive misunderstanding about how effective these treatments really are. Could be a major misstep from
$VKTX CEO, possibly talking their stock down.
In a market full of hype, watch the fundamentals and stay ahead of the curve. The next big move is coming.
